Baloxavir Marboxil (Xofluza) Market: Current Dynamics And Future Outlook 2025 - 2033
- Published: Nov, 2025
- Report ID: GVR-MT-100501
- Format: PDF/Excel databook
- No. of Pages/Datapoints: 120
- Report Coverage: 2024 - 2030
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Baloxavir marboxil (Xofluza) Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Pricing Analysis
Chapter 4. Baloxavir marboxil (Xofluza) Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2033
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
4.4. Acute Uncomplicated Influenza (A and B Strains)
4.4.1. Acute Uncomplicated Influenza (A and B Strains) Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
4.5. Post-Exposure Prophylaxis (PEP)
4.5.1. Post-Exposure Prophylaxis (PEP) Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
Chapter 5. Baloxavir marboxil (Xofluza) Market: Treatment Type Business Analysis
5.1. Treatment Type Market Share, 2024 & 2033
5.2. Treatment Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
5.4. Cap-Dependent Endonuclease Inhibitors (Polymerase Inhibitors)
5.4.1. Cap-Dependent Endonuclease Inhibitors (Polymerase Inhibitors) Market, 2021 - 2033 (USD Million)
5.5. Neuraminidase Inhibitors
5.5.1. Neuraminidase Inhibitors, 2021 - 2033 (USD Million)
Chapter 6. Baloxavir marboxil (Xofluza) Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2033
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
6.4. Oral
6.4.1. Oral (Tablet/Single-Dose) Market, 2021 - 2033 (USD Million)
6.5. Inhalation
6.5.1. Inhalation, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Others Pharmacies, 2021 - 2033 (USD Million)
Chapter 7. Baloxavir marboxil (Xofluza) Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Others, 2021 - 2033 (USD Million)
Chapter 8. Baloxavir marboxil (Xofluza) Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
8.5. Europe
8.6. Asia Pacific
8.7. Latin America
8.8. Middle East and Africa
Chapter 9. Competitive Landscape
9.1. Company Profile
9.1.1. Shionogi & Co., Ltd.
9.1.1.1. Overview
9.1.1.2. Financial Performance
9.1.1.3. Strategic Mapping
9.1.2. Roche Holding AG (Genentech, Inc)
9.1.2.1. Overview
9.1.2.2. Financial Performance
9.1.2.3. Strategic Mapping
9.2. Concurrent Competitive Landscape
9.2.1. F. Hoffmann-La Roche Ltd.
9.2.1.1. Overview
9.2.1.2. Financial Performance
9.2.1.3. Product Benchmarking
9.2.1.4. Strategic Mapping
9.2.2. GlaxoSmithKline plc (GSK)
9.2.2.1. Overview
9.2.2.2. Financial Performance
9.2.2.3. Product Benchmarking
9.2.2.4. Strategic Mapping
9.2.3. BioCryst Pharmaceuticals, Inc.
9.2.3.1. Overview
9.2.3.2. Financial Performance
9.2.3.3. Product Benchmarking
9.2.3.4. Strategic Mapping
9.2.4. Daiichi Sankyo Company, Limited
9.2.4.1. Overview
9.2.4.2. Financial Performance
9.2.4.3. Product Benchmarking
9.2.4.4. Strategic Mapping
9.2.5. Fujifilm Toyama Chemical Co., Ltd.
9.2.5.1. Overview
9.2.5.2. Financial Performance
9.2.5.3. Product Benchmarking
9.2.5.4. Strategic Mapping
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Baloxavir marboxil (Xofluza) Market, by region, 2021 - 2033 (USD Million)
Table 4 North America Baloxavir marboxil (Xofluza) Market, by Indication, 2021 - 2033 (USD Million)
Table 5 North America Baloxavir marboxil (Xofluza) Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 6 Europe Baloxavir marboxil (Xofluza) Market, by Indication, 2021 - 2033 (USD Million)
Table 7 Europe Baloxavir marboxil (Xofluza) Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 8 Asia Pacific Baloxavir marboxil (Xofluza) Market, by Indication, 2021 - 2033 (USD Million)
Table 9 Asia Pacific Baloxavir marboxil (Xofluza) Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 10 Latin America Baloxavir marboxil (Xofluza) Market, by Indication, 2021 - 2033 (USD Million)
Table 11 Latin America Baloxavir marboxil (Xofluza) Market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 12 Middle East & Africa Baloxavir marboxil (Xofluza) Market, by Indication, 2021 - 2033 (USD Million)
Table 13 Middle East Baloxavir marboxil (Xofluza) Market, by Distribution Channel, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Baloxavir marboxil (Xofluza) Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market End User & validation
Fig. 8 Market snapshot
Fig. 9 Indication outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Baloxavir marboxil (Xofluza) Market dynamics
Fig. 12 Baloxavir marboxil (Xofluza) Market: Porter’s five forces analysis
Fig. 13 Baloxavir marboxil (Xofluza) Market: PESTLE analysis
Fig. 14 Indication market, 2021 - 2033 (USD Million)
Fig. 15 Acute Uncomplicated Influenza (A and B Strains) market, 2021 - 2033 (USD Million)
Fig. 16 Post-Exposure Prophylaxis (PEP) market, 2021 - 2033 (USD Million)
Fig. 17 Treatment Type market, 2021 - 2033 (USD Million)
Fig. 18 Cap-Dependent Endonuclease Inhibitors (Polymerase Inhibitors) market, 2021 - 2033 (USD Million)
Fig. 19 Neuraminidase Inhibitors market, 2021 - 2033 (USD Million)
Fig. 20 Route of Administration market, 2021 - 2033 (USD Million)
Fig. 21 Oral market, 2021 - 2033 (USD Million)
Fig. 22 Inhalation market, 2021 - 2033 (USD Million)
Fig. 23 Others market, 2021 - 2033 (USD Million)
Fig. 24 Distribution Channel market, 2021 - 2033 (USD Million)
Fig. 25 Hospital Pharmacies market, 2021 - 2033 (USD Million)
Fig. 26 Retail Pharmacies market, 2021 - 2033 (USD Million)
Fig. 27 Others market, 2021 - 2033 (USD Million)
Fig. 28 Baloxavir marboxil (Xofluza) Market revenue, by region
Fig. 29 Regional marketplace: Key takeaways
Fig. 30 North America Baloxavir marboxil (Xofluza) Market, 2021 - 2033 (USD Million)
Fig. 31 Europe Baloxavir marboxil (Xofluza) Market, 2021 - 2033 (USD Million)
Fig. 32 Asia Pacific Baloxavir marboxil (Xofluza) Market, 2021 - 2033 (USD Million)
Fig. 33 Latin America Baloxavir marboxil (Xofluza) Market, 2021 - 2033 (USD Million)
Fig. 34 MEA Baloxavir marboxil (Xofluza) Market, 2021 - 2033 (USD Million)
Fig. 35 Company categorization
Fig. 36 Company market position analysis
Fig. 37 Strategic framework
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.